Observations on the intracoronary administration of milrinone and dobutamine to patients with congestive heart failure
- PMID: 2909993
- DOI: 10.1016/0002-9149(89)90387-1
Observations on the intracoronary administration of milrinone and dobutamine to patients with congestive heart failure
Abstract
A direct intracoronary infusion technique was used to characterize the mechanisms of action of milrinone, a new phosphodiesterase inhibitor. Because of the small quantity of drug infused, it is possible to achieve a therapeutic concentration of drug in the heart with little or no systemic accumulation. Because loading conditions are largely unaffected during intracoronary drug infusion, it is possible to use left ventricular +dP/dt as a convenient measure of changes in contractility. Intracoronary milrinone infusion caused a dose-related increase in +dP/dt associated with a substantial improvement in left ventricular pump function. In addition, there is a small decrease in heart rate, which appeared to be secondary to reflex withdrawal of sympathetic tone, since it was associated with a decrease in plasma norepinephrine. Measurement of forearm vascular resistance and forearm venous capacitance by plethysmography indicated that although there was no significant decrease in forearm vascular resistance during intracoronary drug infusion, there was a small increase in venous capacitance. Subsequent intravenous administration of milrinone caused a substantial further improvement in left ventricular pump function, associated with a substantial decrease in left- and right-sided cardiac filling pressures and forearm vascular resistance, and an increase in forearm venous capacitance. These findings suggest that reflex sympathetic withdrawal may contribute to the venous dilation that occurs with milrinone, but that the major effects of milrinone on vascular tone are due to a direct vascular action of the drug. Intracoronary infusion of dobutamine has also demonstrated a substantial decrease in the inotropic response to beta-adrenergic stimulation in patients with congestive heart failure, presumably because of down-regulation of beta-adrenergic receptors.(ABSTRACT TRUNCATED AT 250 WORDS)
Similar articles
-
Intracoronary infusion of dobutamine to patients with and without severe congestive heart failure. Dose-response relationships, correlation with circulating catecholamines, and effect of phosphodiesterase inhibition.J Clin Invest. 1988 Apr;81(4):1103-10. doi: 10.1172/JCI113423. J Clin Invest. 1988. PMID: 2832444 Free PMC article.
-
Myocardial and vascular actions of milrinone.Eur Heart J. 1989 Aug;10 Suppl C:32-8. doi: 10.1093/eurheartj/10.suppl_c.32. Eur Heart J. 1989. PMID: 2680495 Review.
-
Milrinone and dobutamine in severe heart failure: differing hemodynamic effects and individual patient responsiveness.Circulation. 1986 Mar;73(3 Pt 2):III175-83. Circulation. 1986. PMID: 3510774 Clinical Trial.
-
Separation of the direct myocardial and vasodilator actions of milrinone administered by an intracoronary infusion technique.Circulation. 1986 Jan;73(1):130-7. doi: 10.1161/01.cir.73.1.130. Circulation. 1986. PMID: 3940664
-
In vivo studies of myocardial beta-adrenergic receptor pharmacology in patients with congestive heart failure.Circulation. 1990 Aug;82(2 Suppl):I44-51. Circulation. 1990. PMID: 2164896 Review.
Cited by
-
Current status of phosphodiesterase inhibitors in the treatment of congestive heart failure.Drugs. 1992 Dec;44(6):928-45. doi: 10.2165/00003495-199244060-00003. Drugs. 1992. PMID: 1282864 Review.
-
Use of milrinone in cardiac surgical patients.Cardiovasc Drugs Ther. 1993 Aug;7(4):671-5. doi: 10.1007/BF00877820. Cardiovasc Drugs Ther. 1993. PMID: 8241010 Review.
-
Adrenergic and muscarinic receptor regulation and therapeutic implications in heart failure.Mol Cell Biochem. 1996 Apr 12-26;157(1-2):251-8. doi: 10.1007/BF00227907. Mol Cell Biochem. 1996. PMID: 8739255 Review.
-
Mechanism underlying the reduced positive inotropic effects of the phosphodiesterase III inhibitors pimobendan, adibendan and saterinone in failing as compared to nonfailing human cardiac muscle preparations.Naunyn Schmiedebergs Arch Pharmacol. 1991 Jul;344(1):90-100. doi: 10.1007/BF00167387. Naunyn Schmiedebergs Arch Pharmacol. 1991. PMID: 1723153
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical